REFERENCES

1. NIH (National Institutes of Health), Institute of Medicine. Clearing the smoke. Assessing the science base for tobacco harm reduction. Stratton K, Shetty P, Wallace R, and Bondurant S, editors. Washington D.C.: National Academy Press; 2001.
2. Byrd GD, Robinson JH, Caldwell WS, deBethizy JD. Comparison of measured and FTC-predicted nicotine uptake in smokers. Psychopharmacology 1995;122:95-103
3. Federal Trade Commission. Cigarettes: Testing for tar and nicotine content – Statements for considerations. Fed. Register 1997;32:11178.
4. Bridges RB, Combs JG, Humble JW, Turbek JA, Rehm SR, Haley NJ. Puffing topography as a determination of smoke exposure. Pharmacol Biochem Behav 1990;37:29-39
5. Hofer I, Nil R, Battig K. Nicotine yield as determinant of smoke exposure indicators and puffing behavior. Pharmacol Biochem Behav 1991;40(1):139-49.
6. Castleden CM, Cole PV. Variations in carboxyhaemoglobin levels in smokers. Br Med J 1974;4:736-8.
7. Boswell CS, Curwall M, Elswick RK, Leyden DE. Modeling nicotine intake in smokers and snuff users using biological fluid nicotine metabolites. Biomarkers 2000;5(5):341-354.
8. Curvall M, Kazemi-Vala E, Englung G. Conjugation pathways in nicotine metabolism. In: Adlkofer F, Thurau K. editors. Effects of nicotine on biological systems. Basle: Birkhauser; 1991. p. 69-74.
9. Baker RR. Smoke chemistry. In: Davis DL., Nielsen MT, editors. Tobacco production, chemistry and technology. Oxford: CORRESTA; 1999. p.398-439.
10. World Health Organization. Environmental Health Criteria 213: Carbon monoxide. 2nd ed. Geneva: World Health Organization; 1999.
11. Varon J, Marik PE, Fromm RE, Gueler A. Carbon monoxide poisoning: a review for clinicians. J Emergency Med 1999;17:87-93.
12. Benowitz NL. Biomarkers of environmental tobacco smoke exposure. Environ Health Perspect 1999;107 Suppl 2:349-355.

PM3001149081

Source: https://www.industrydocuments.ucsf.edu/docs/jxgk0001

13. Benowitz NL, Jacob P, Jones RT, Rosenberg J. Interindividual variability in the metabolism and cardiovascular effects of nicotine in man. J Pharmacol Exp Ther 1982;221-368-372.
14. Kyerematen GA, Vesell ES. Nicotine metabolism. Drug Metab Rev 1991;23:3-41.
15. Ross R. Atherosclerosis: an inflammatory disease. NEJM 1999;340:115-126.
16. Morrow JD, Zackert WE, Van der Ende DS, Reich EE, Terry ES, Cox B, Sanchez SC, Montine TJ, Roberts LJ. Quantification of isoprostanes as indicators of oxidant stress in vivo. In: Cardenas E, Packer L, editors. Handbook of antioxidants. New York: Marcel Decker; 2002. p. 57-74.
17. Pilacik B, Nofer TW, Wasowicz W. F_2-isoprostanes biomarkers of lipid peroxidation: their utility in evaluation of oxidative stress induced by toxic agents. International J Occupational Medicine and Environmental Health 2002;15(1):19-27.
18. Ernst E, Matrai A, Schmolzl C, Agyarosy I. Dose-effect relationship between smoking and blood rheology. Br J Haematol 1987;65:485-487.
19. Pepys MB, Baltz ML. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol 1983;34:141-212.
20. Wilkins J, Gallimore JR, Moore EG, Pepys MB. Rapid automated high sensitivity enzyme immunoassay of C-reactive protein. Clin Chem 1998;44(6 Pt 1):1358-1361.
21. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, Hutchinson WL, Pepys MB. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation. 1999;99(2):237-242.
22. Ridker PM, Haughie P. Prospective studies of C-Reactive protein as a risk factor for cardiovascular disease. J Investig Med. 1998;46(8):391-395.
23. Tracy RP, Psaty BM, Macy E, Bovill EG, Cushman M, Cornell ES, Kuller LH. Lifetime smoking exposure affects the association of C-reactive protein with

PM3001149082

Source: https://www.industrydocuments.ucsf.edu/docs/jxgk0001

cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscl Thromb Vasc Biol. 1997;17:2167-2176.

24. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparation ultracentrifuge. Clin Chem 1972;18:499-502.
25. Cushman M, Legault C, Barrett-Connor E, Stefanick ML, Kessler C, Judd HL, Sakkinen PA, Tracy RP. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circ 1999;100:717-722.
26. Cushman M, et al. Hormone replacement therapy, inflammation and hemostasis in elderly women. Arterioscl Thromb Vasc Biol 1999;19:893-899.
27. Craig WY, Palomaki GE, Haddow JE. Cigarette smoking and serum lipid and lipoprotein concentrations: An analysis of published data. Br Med J 1989;298:734-788.
28. Superko HR. Lipoproteins and oxidation: clinical aspects of lipoprotein metabolism and oxidation. In: Tardif JC, Bourassa MG, editors. Antioxidants and cardiovascular disease. Dordrecht: Kluwer Academic Publishers; 2000. p.1-17.
29. Cracowski JL, Durand T, Bessard G. Isoprostanes as a biomarker of lipid peroxidation in humans: physiology, pharmacology and clinical implications. Trends in Phamacol Sci 2002;23(8):360-366.
30. Chehne F, Oguogho A, Lupattelli G, Budinsky AC, Palumbo B, Sinzinger H. Increase of isoprostane 8-epi-PGF_{2a} after restarting smoking. Leukot and Essent Fatty Acids 2001;64(6):307-310.
31. Yarnell JW, Sweetnam PM, Rumley A, Lowe GD. Lifestyle and hemostatic risk factors for ischemic heart disease: the Caterphilly study. Arterioscler Thromb Vasc Biol 2000;20:271-279.
32. Byrd GD, Davis RA, Caldwell WS, Robinson JH, deBethizy JD. A further study of FTC yield and nicotine absorption in smokers. Psychopharmacology 1998;139:291-299.

PM3001149083

Source: https://www.industrydocuments.ucsf.edu/docs/jxgk0001

33. Ueda K, Kawachi I, Nakamura M, Nogami H, Shirokawa N, Masui S, Okayama A, Oshima A. Cigarette nicotine yields and nicotine intake among Japanese male workers. Tobacco Control 2002;11:55-60.
34. Tobacco Institute Testing Laboratory Market Sample 43 Test Results. "Tar", "Nicotine", and Carbon Monoxide Values. Rockville, MD; 2001 April 27.
35. Benowitz NL, Jacob P, Fong I, Gupta S. Nicotine metabolic profile in man: comparison of cigarette smoking and transdermal nicotine. J Pharmacol Exp Ther 1994;268(1):296-303.
36. Kinser RD, Nelson BL, Roethig, HJ, Walk RA, Oey J, Tricker AR, Leyden DE. Assessment of human exposure to cigarette smoke constituents: pilot study results for carbon monoxide. Toxicol Sci 2002;66 Suppl 1: Abstract LB94:26.
37. Benowitz NL. The use of biologic fluid samples in assessing tobacco smoke consumption. In: Grabowski J, Bell CS, editors. NIDA Res Monogr. 1983;48:6-26.
38. FDA Guidance for Industry: Bioanalytical Method Validation. 2001 May. http://www.fda.gov/cder/guidance/4252fnl.pdf
39. Klesges LM, Klesges RC, Cigrang JA. Discrepancies between self-reported smoking and carboxyhemoglobin: an analysis of the second National Health and Nutrition Survey. Amer J Public Health 1992;82:1026-1029.
40. Burtis CA, Ashwood ER, editors. Tietz Textbook of Clinical Chemistry. Philadelphia: W. B. Saunders Company; 1999. p. 1245.
41. Maxwell JC, Fenstermacher SD. The Maxwell Consumer Report. Richmond (VA): Davenport & Company; 1999 March.
42. Schepers G, Demetriou D, Rustemeier K, Voncken P, Diehl B. Nicotine phase 2 metabolites in human urine—structure of metabolically formed *trans*-3'-hydroxycotinine glucuronide. Poster presented at the Society for Research on Nicotine and Tobacco meeting; 2001 October;Minneapolis, MN.

Robin
please
check
for accuracy
& completeness
Barb

PM3001149084

Source: https://www.industrydocuments.ucsf.edu/docs/jxgk0001